Validation of an HPLC method for the simultaneous quantification of metabolic reaction products catalysed by CYP2C11 enzymes in rat liver Microsomes : in vitro inhibitory effect of salicylic acid on CYP2C11 enzyme by Salhab, Hassan et al.
  
Molecules 2019, 24, 4294; doi:10.3390/molecules24234294 www.mdpi.com/journal/molecules 
Article 
Validation of an HPLC Method for the Simultaneous 
Quantification of Metabolic Reaction Products 
Catalysed by CYP2C11 Enzymes in Rat Liver 
Microsomes: In Vitro Inhibitory Effect of Salicylic 
Acid on CYP2C11 Enzyme 
Hassan Salhab *, Declan P. Naughton and James Barker 
School of Life Sciences, Pharmacy and Chemistry, Kingston University, Kingston upon Thames,  
London KT1 2EE, UK; d.naughton@kingston.ac.uk (D.P.N.); j.barker@kingston.ac.uk (J.B.) 
* Correspondence: K1542808@kingston.ac.uk; Tel.: +447984974741; Fax: +442084179000 
Academic Editor: Makoto Tsunoda 
Received: 01 October 2019; Accepted: 20 November 2019; Published: 25 November 2019 
Abstract: The inhibitory effect of new chemical entities on rat liver P450 marker activities was 
investigated in a functional approach towards drug development. Treatment of colorectal cancer 
(CRC) and chemoprevention using salicylic acid has gained a lot of attention, mainly in the 
prevention of the onset of colon cancer. Thus, an in vitro inhibitory effect of salicylic acid on rat 
CYP2C11 activity was examined by using high performance liquid chromatography (HPLC). High 
performance liquid chromatography analysis of a CYP2C11 assay was developed on a reversed 
phase C18 column (SUPELCO 25 cm × 4.6 mm × 5 µm) at 243 nm using 32% phosphate buffer (pH 
3.36) and 68% methanol as a mobile phase. The CYP2C11 assay showed good linearity for all 
components (R2 > 0.999). Substrates and metabolites were found to be stable for up to 72 hours. 
Additionally, the method demonstrated good reproducibility, intra- and inter-day precision (<15%), 
acceptable recovery and accuracy (80%–120%), and low detection (1.3501 µM and 3.2757 µM) and 
quantitation limit values (4.914 µM and 9.927 µM) for 16α-hydroxytestosterone and testosterone, 
respectively. Salicylic acid acts reversibly as a noncompetitive (weak) inhibitor with Ki = 84.582 ± 
2.67 µM (concentration of inhibitor to cause 50% inhibition of original enzyme activity (IC50) = 82.70 
± 2.67 µM) for CYP2C11 enzyme activity. This indicates a low potential to cause toxicity and drug–
drug interactions. 
Keywords: cytochrome P450; HPLC; 16α-hydroxytestosterone; phenacetin; salicylic acid; 
testosterone 
 
1. Introduction 
Cytochrome P450s are known as Phase 1 mono-oxygenase drug-mediated enzymes that play a 
vital role as a body defence in the drug pharmacokinetic field [1]. Cytochrome P450s have the ability 
to transform biologically xenobiotic drugs, such as steroids, fatty acid derivatives, hormones, and 
endogenous and exogenous molecules, into more lipophobic molecules (more polar functional 
groups) [2]. CYP450 drug metabolising enzymes are located predominantly in the liver, whereas a 
few of them are expressed in other human body organs, such as the small intestine, kidneys, lungs 
and placenta [3]. Statistical results have shown that about 70%–80% of most marketed drugs are 
metabolised by five major Phase 1 drug mediated enzymes [4]. 
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Nowadays, toxicity and bioavailability issues are the most common obstacles in the drug 
development field [4]. Therefore, induction or inhibition of CYP450 enzymes can result in either 
drug–drug or drug–herb interactions, and their effectiveness can be altered [5]. Thus, this leads to a 
therapeutic failure in the treatment [3]. Understanding the concept of inhibition and induction 
pathways can help in reducing the interaction between drugs and occurrence of adverse reactions 
[3]. Inhibition of CYP450 enzymes by drugs can lead to a rise in the concentration of other 
metabolising drugs, thus causing drug toxicity problems [6].  
The CYP2C11 isoform is the most dominant isoform in male-specific rat liver microsomes and 
accounts for 50% of the total male-specific male rat hepatocytes [7]. Wojcikowski et al. [7] stated that 
testosterone is metabolised to either 16α-hydroxytestosterone or 2α-hydroxytestosterone by means 
of CYP2C11 enzyme activity in male-specific rat liver microsomes. Previous studies showed that 
some inflammatory mediators, such as ethanol, cimetidine and diclofenac, extensively inhibit the 
CYP2C11 isoform [7]. Thus, both 2α and 16α-hydroxytestosterone are used as markers in studying 
CYP2C11 enzyme activity in rat liver microsomes [7].    
Salicylic acid (Figure 1) belongs to a nonsteroidal, anti-inflammatory drug class, which plays a 
vital role in the reduction of gastrointestinal tumours [8]. However, recent studies revealed that 
salicylic acid can cause liver damage [9]. These studies have shown that salicylic acid can be 
metabolised to six metabolites using various quantitative analytical techniques, such as HPLC and 
liquid chromatography tandem mass spectrometry (LC-MS/MS) [10]. Salicylic acid inhibits the 
metabolism of fatty acid based on the acyl chain length [11]. These studies suggested that salicylic 
acid can be linked to the interference of fatty acid metabolism by reducing [C14] CO2 from fatty acid 
and increasing the amount of uncoupled fatty acid in the plasma. Until now, various papers on the 
pharmacokinetics and metabolism of salicylic acid have been reported, but only one paper [9] has 
shown that the oxidative metabolism of salicylic acid is mediated by CYP2E1 and CYP2C11 enzymes 
in rat liver microsomes. 
 
Figure 1. Structure of salicylic acid. 
Consequently, an analytical HPLC method was validated, which studies the in vitro inhibitory 
effect of salicylic acid on the activities of major cytochrome CYP450s (CYP2C11) as an example for 
promoting the safety and efficacy of salicylic acid in clinics.  
2. Results and Discussion 
2.1. Selection of Analytical Wavelength: UV-VIS (Ultraviolet-visible) Spectroscopy (CYP2C11 Assay): 
UV-VIS spectrophotometry analysis for CYP2C11 assay was performed by dissolving salicylic 
acid (100 µM), testosterone (200 µM) and 16-α hydroxytestosterone (50 µM) powder in pure methanol 
(wavelength cut-off of methanol was 210 nm). 
The following graph illustrates the measurements of maximum wavelength of each component 
in the CYP2C11 assay.  
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Figure 2. Overlain spectra of salicylic acid, testosterone and 16α-hydroxytestosterone components in 
the CYP2C11 assay. 
From overlain spectra of CYP2C11 assay compounds (Figure 2) and (Figure S1), it is shown that 
the maximum of the absorption band for all four CYP2C11 components is 243 nm, and so this was 
chosen for our study. 
2.2. Method Validation 
2.2.1. Linearity and Range 
Different concentrations of testosterone and its metabolite (16α-hydroxytestosterone) solutions 
(mentioned in Section 3.6.1) were analysed by HPLC for the production of standard calibration 
curves. Calibration curves were constructed by plotting the mean area peak of standards and 
phenacetin (internal standard) versus the concentration of standard (substrate and metabolite). The 
outcomes are listed in Table 1. Good linearities for both testosterone and 16α-hydroxytestosterone 
were obtained, with r2 values of 0.9999 and 0.9998, respectively. The linear regression coefficient was 
within the acceptable range (r2 > 0.99), according to ICH (International Conference on Harmonization) 
guidelines. Relative standard deviations (%RSD) at each different concentration (<5%) met the ICH 
guidelines [12]. 
Table 1. Analytical performances. 
Standards Testosterone 16α-hydroxytestosterone 
Regression equation Y = 0.0189X − 0.0203 Y = 0.0204X − 0.0036 
            r2 0.9999 0.9998 
Linear range 10–400 µM 10–100 µM 
2.2.2. Limit of Detection (LOD) and Limit of Quantitation (LOQ) 
According to ICH Technical Requirements for Registration of Pharmaceuticals for Human Use, 
the LOD and LOQ of the proposed method were calculated mathematically by the relationship 
between the slope of the calibration curve and the standard deviation of the response using the 
following equations 
LOD = 3.3σ/S LOQ = 10σ/S 
where σ is the standard deviation of the response; S is the slope of the calibration curve. 
         Reference (methanol) 
         16α-hydroxytestosterone  
         Testosterone 
         Salicylic acid 
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The results presented in Table 2 demonstrate that both testosterone and 16α-
hydroxytestosterone have detection values in the range of 1–4 µM and quantitation values in the 
range of 4–10 µM, which is consistent with the literature [13]. 
Table 2. Limit of detection (LOD) and limit of quantitation (LOQ) for testosterone and 16α-
hydroxytestosterone. 
Standards Testosterone 16α-hydroxytestosterone 
Limit of Detection (LOD) 3.276 µM 1.350 µM 
Limit of Quantitation (LOQ) 9.927 µM 4.914 µM 
2.2.3. Specificity and Selectivity 
Specificity tests were performed by using spiked samples (50 µM of phenacetin dissolved in 30% 
of phosphate buffer (pH 3.36) + 70% of methanol) to evaluate that the method outcomes were not 
affected by the impurities.  
Specificity was achieved by choosing the right mobile phase composition (phosphate buffer at 
pH 3.36 (A) + methanol (B)) using low pressure isocratic elution programming: 68% methanol + 32% 
phosphate buffer at pH = 3.36. This results in good separation of the enzyme peak (NADPH 
(Nicotinamide Adenine Dinucleotide Phosphate Hydrogen)-regenerating system) from the CYP2C11 
metabolite (16α-hydroxytestosterone), salicylic acid, phenacetin and testosterone peaks at T = 25 °C, 
using a C18 (SUPELCO 25 cm × 4.6 mm, 5 µm) column at 0.8 mL/min flow rate and a wavelength of 
λ = 243 nm (Figure 3). 
 
Figure 3. Typical HPLC chromatogram of CYP2C11 components in standard rat microsomal medium 
at 243 nm wavelength detection and a concentration of 150 µM testosterone. The peaks marked are: 
(1) NADPH (Nicotinamide Adenine Dinucleotide Phosphate Hydrogen)-regenerating system; (2) 
salicylic acid (100 µM); (3) phenacetin; (4) 16α-hydroxytestosterone; and (5) testosterone respectively. 
2.2.4. Precision 
Intra-Assay Variation of Testosterone and 16α-hydroxytestosterone 
Intra-assay variation of testosterone and 16α-hydroxytestosterone was determined by 
measuring three testosterone concentration levels (200, 100, and 25 µM, representing high, medium, 
and low levels, respectively) and three 16α-hydroxytestosterone concentration levels (80, 40, 10 µM, 
representing high, medium, and low levels, respectively) 3 times in a single batch (n = 3). The 
outcomes, summarised in Tables 3 and 4, illustrate that the %RSD (relative standard deviation) was 
< 5% for testosterone and 16α-hydroxytestosterone. The experiment revealed that there is no 
significant variation in intra-assay measurements. 
1 
2 
3 
4 
5 
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Table 3. Intra-assay variation for testosterone (n = 3). 
Testosterone standard Mean activity a 
(µM) 
Standard deviation  Relative Standard deviation (%) 
Low-activity standard (C = 25 µM) 22.8856 0.4851 2.1198 
Medium-activity standard (C = 100 µM) 102.7028 0.6444 0.6275 
High-activity standard (C = 200 µM) 201.2282 4.9342 2.4520 
a Mean found concentration (µM). 
Table 4. Intra-assay variation for 16α-hydrotestosterone (n = 3). 
16α-hydroxytestosterone standard Mean activity a (µM) Standard deviation Relative Standard deviation (%) 
Low-activity standard (C = 10 µM) 8.5631 0.3848 4.4946 
Medium-activity standard (C = 40 µM) 31.0608 0.3516 1.1322 
High-activity standard (C = 80 µM) 67.9271 0.2154 0.3172 
a Mean found concentration (µM). 
Inter-Assay Variation of Testosterone and 16α-hydroxytestosterone 
Inter-assay variation was determined by measuring testosterone standards of three 
concentrations levels (200, 100, and 25 µM, representing high, medium, low levels, respectively) and 
16α-hydroxytestosterone (80, 40, 10 µM) for three consecutive days, in separate batches. The results, 
summarised in Tables 5 and 6, illustrate that the relative standard deviation or %RSD was <10% for 
testosterone and 16α-hydroxytestosterone. The experiment revealed that there is no significant 
variation between aliquots of the same batch sample in inter-assay measurements. 
Table 5. Inter-assay variation for testosterone. 
Testosterone standard (µM) Mean Area peak (n 
= 3 each level) 
Mean a 
activity (µM) 
Standard 
deviation 
Relative standard 
deviation (%) 
Low-activity standard 
(C = 25 µM) 
Day 1 0.7057 
24.3194 0.6826 2.8068 Day 2 0.5725 
Day 3 0.8314 
Medium-activity 
standard 
(C = 100 µM) 
Day 1 2.9393 
101.7997 2.0495 2.0133 Day 2 2.3360 
Day 3 3.4765 
High-activity standard 
(C = 200 µM) 
Day 1 5.9357 
210.938 8.8989 4.2187 Day 2 4.8596 
Day 3 7.3105 
a Mean concentration (µM). 
Table 6. Inter-assay performance of 16α-hydroxytestosterone. 
16α-hydroxytestosterone 
standard (µM) 
Mean Area peak 
(n = 3 each level) 
Mean a activity 
(µM) 
Standard deviation Relative standard 
deviation (%) 
Low-activity 
standard (C = 10 µM) 
Day 1 0.1932 
10.5557 0.7102 6.7286 Day 2 0.3154 
Day 3 0.1227 
Medium-activity 
standard 
(C = 40 µM) 
Day 1 0.7802 
38.1011 2.6567 6.9730 Day 2 1.2850 
Day 3 0.4912 
High-activity 
standard (C = 80 µM) 
Day 1 1.6356 
79.7765 2.4168 3.0295 Day 2 2.6480 
Day 3 1.1200 
a Mean concentration (µM). 
2.2.5. Stability Test 
Stability Test of Testosterone  
The stability of testosterone was investigated at three different concentrations (25, 100, and 200 
µM, representing low, medium and high levels, respectively), which were chosen as an 
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approximation of its Km [14], and stored for 72 hours at room temperature in natural light conditions. 
Phenacetin (as an internal standard of 50 µM) was added to each batch. Samples were analysed in 
triplicate (n = 3) for each batch. The stability test results are summarised in Table 7. 
Table 7. Stability test data for testosterone. 
 
Nominal level (actual concentration of testosterone (µM)) 
 25 100 200 
Calculated 
concentration (µM) 
0 h 20.0423 80.1101 159 
24 h 21.6355 80.1101 159 
48 h 21.5520 86.0148 162.3135 
72 h 21.4054 80 163.3444 
% Recovery a 
24 h 107.9492 100 100 
48 h 107.5323 107.3707 102.0839 
72 h 106.8007 99.8624 102.7323 
Accuracy b (%) 
0 h 119.8305 119.8898 120.5 
24 h 113.4576 119.8898 120.5 
48 h 113.7918 113.9851 118.8432 
72 h 114.3783 120 118.3277 
Note: a % recovery = (concentration of testosterone at 24 hours/standard concentration of testosterone) 
× 100; b Accuracy = 100 − ((calculated concentration − actual concentration)/actual concentration) × 100. 
The outcomes revealed that there was no variation in the concentration or changes in 
chromatographic behavior of testosterone at 0, 24, 48, and 72 hours, compared to actual 
concentrations. Calibration curves were plotted for days 1−4 and all four calibration curves were 
averaged, hence the average calibration curve equation was: y = 0.0236x − 0.0406 (R2 = 0.9997), where 
r2 met ICH guidelines. LOD and LOQ values were 5.4408 and 16.4874 µM, respectively. Percentage 
recovery for testosterone at concentrations of 25, 100 and 200 µM was found to be within an 
acceptable range (80%–120%), according to ICH guidelines, and thus the results show high and 
acceptable accuracy (80%–120%) for testosterone concentrations of 25 and 100 µM. On the other hand, 
at 200 µM concentration, the accuracy was just beyond the acceptable value of 120.5% for 0 and 24 
hours. The results indicate that testosterone solution was relatively stable for 72 hours at ambient 
temperature, which is consistent with the literature [15]. 
Stability Test of 16α-hydroxytestosterone  
Stability of CYP2C11 metabolite (16-alfa hydroxytestosterone) was investigated for three 
different concentrations (10, 40, and 80 µM) stored for 72 hours and kept at room temperature in 
natural light conditions. Three different concentration ranges of 16-alfa hydroxytestosterone were 
chosen, since the amount of metabolite formed at 200 µM of testosterone was 35 µM, meaning it was 
necessary to investigate the stability of the metabolite at low, medium, and high concentrations. 
Phenacetin (as an internal standard of 50 µM) was added to each batch. The sample was analysed in 
triplicate (n = 3) for each batch. The stability test results are summarised in Table 8. 
Table 8. Stability test data of 16-alfa hydroxytestosterone. 
 
Nominal level (Actual concentration of 16-alfa hydroxytestosterone (µM)) 
 10 40 80 
Calculated 
concentration (µM) 
0 h 10.533 38.0055 77.5659 
24 h 10.9725 41.3021 88.5549 
48 h 11.1923 44.2142 91.8516 
72 h 10.4 35.0866 76.5 
% Recovery a 
24 h 109.725 103.2552 110.6936 
48 h 111.923 110.5355 114.8145 
72 h 104 87.7165 95.625 
Accuracy b (%) 
0 h 94.67 104.9862 103.0426 
24 h 90.275 96.7448 89.3064 
48 h 88.077 89.4645 85.1855 
72 h 96 112.2835 104.375 
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Note: a % recovery = (concentration of testosterone at 24 hours/standard concentration of testosterone) 
× 100; b Accuracy = 100 − ((calculated concentration − actual concentration)/actual concentration) × 100. 
The results presented in Table 8 show that there was no variation in the concentration or in 
changes in chromatographic behaviour of 16-alfa hydroxytestosterone at 0, 24, 48 and 72 hours 
compared to actual concentrations. Calibration curves were plotted for days 1–4 and all four 
calibration curves were averaged, hence the average calibration curve equation was: y = 0.0182x – 
0.0117 (r2 = 0.9992), where r2 met the ICH guidelines. Percentage recovery for 16-alfa 
hydroxytestosterone at concentrations of 10, 40 and 80 µM was found to be within acceptable ranges 
(80%–120%), according to ICH guidelines. Thus, the results show high and acceptable accuracy (80%–
120%) for 16-alfa hydroxytestosterone concentrations of 10, 40 and 80 µM compared with the 
standard known concentration. Therefore, the results indicate that 16-alfa hydroxytestosterone 
solution was stable for 72 hours at room temperature, which is consistent with the literature [16]. 
2.2.6. Robustness Test 
Changing the Percentage of the Mobile Phase 
A robustness study was performed by changing the percentage of the mobile phase (increasing 
the percentage of methanol by 2%) using HPLC, and evaluating the effect on retention time and peak 
area of each compound. Table 9 shows the change in mobile phase ratio on both retention time and 
peak area of each compound.  
Table 9. Retention time, peak area and resolution variation upon using two different mobile phase 
composition modes at a flow rate of 0.8 mL/min. 
Mobile Phase 
composition Compounds 
Average 
Retention time 
(n=3) (min) 
Average 
Area peak 
(n=3) (Arb 
units) 
Resolution 
70% Methanol + 30% 
Phosphate buffer at 
pH = 3.36 
Salicylic acid (100 µM) 3.468 63443 
16α-hydroxytestosterone and 
phenacetin were well separated 
(good resolution) 
(Difference in retention time = 
0.842 min). 
Phenacetin (50 µM) 4.512 143502 
Testosterone (200 µM) 10.726 644120 
16α- 
hydroxytestosterone 
(50 µM) 
5.354 222620 
68% Methanol + 32% 
Phosphate buffer at 
pH = 3.36 
Salicylic acid (100 µM) 3.572 67994 16α-hydroxytestosterone and 
phenacetin were well separated 
from each other 
(very good resolution) 
(Difference in retention time = 
1.083 min). 
 
Phenacetin (50 µM) 4.730 141116 
Testosterone (200 µM) 12.359 641325 
16α- 
hydroxytestosterone 
(50 µM) 
5.813 216239 
Overall, retention time, peak area and resolution for salicylic acid, phenacetin, testosterone and 
16α-hydroxytestosterone did not vary when changing the composition of methanol by 2%, except 
that testosterone eluted later (tR = 12.359 min) when the concentration of methanol decreased by 2%. 
This means that testosterone is more soluble in organic solvent than aqueous medium. A mobile 
phase consisting of 68% methanol with 32% phosphate buffer at pH 3.36 was chosen because the 
resolution between phenacetin and 16-alfa hydroxytestosterone peaks (1.083 min) was greater than 
the resolution between phenacetin and 16-alfa hydroxytestosterone peaks (0.842 min) when using 
70% methanol with 30% phosphate buffer at pH 3.36. This implies that the CYP2C11 assay method is 
robust, considering the change in mobile phase ratio. 
Changing the Column Temperature 
A robustness study was conducted by considering the change in column temperature on HPLC, 
by evaluating the effect on retention time and peak area of each compound. As 30 °C was the optimum 
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column temperature for HPLC, thus 25 °C was selected, as it is ± 5 °C. Table 10 shows the effect of 
temperature on both retention time and peak area of each compound in CYP2C11 assay. 
Table 10. Retention time and peak area variation using two different column temperatures. 
Mobile Phase 
composition 
Compounds 
Average 
Retention 
time (n=3) 
(min) 
Average 
Area peak 
(n = 3) 
Resolution 
68% Methanol + 32% 
Phosphate buffer at pH = 
3.36 at a flow rate = 0.8 
mL/min and T = 25 °C 
Salicylic acid (100 µM) 3.549 50965 
All compounds were well 
separated from each other. 
Difference in retention time 
between salicylic acid and 
phenacetin was 1.287 min. 
Phenacetin (50 µM) 4.836 135948 
Testosterone (200 µM) 13.287 597882 
16α- 
hydroxytestosterone 
(50 µM) 
6.025 184493 
68% Methanol + 32% 
Phosphate buffer at pH = 
3.36 at a flow rat e= 0.8 
mL/min and T = 300C 
Salicylic acid(100 µM) 3.492 50536 
All components were well 
separated from each other. 
Difference in retention time 
between salicylic acid and 
phenacetin was 1.26 min. 
Phenacetin (50 µM) 4.752 136505 
Testosterone (200 µM) 12.472 
598229 
 
16α- 
hydroxytestosterone 
(50 µM) 
5.854 175528 
The peak area and the retention time for each component in the CYP2C11 assay remained 
unaffected when the temperature was changed from 30 °C to 25 °C. However, testosterone eluted 
earlier when the temperature increased from 25 °C to 30 °C. A temperature of 25 °C was chosen in this 
analytical method, because the resolution between salicylic acid and the phenacetin peak (1.287 min) 
at 25 °C was greater than the resolution between salicylic acid and the phenacetin peak (1.26 min) at 
30 °C. Overall, this method is robust, considering the change in column temperature. 
2.3. Effects of Salicylic acid on CYP2C11 Activity 
Different concentrations of testosterone (25, 50, 100, 150 and 200 µM) were incubated in the 
presence of 0, 50, 100 and 200 µM salicylic acid using 0.5 mg/mL of rat liver microsome with 1.0 mM 
NADPH (Nicotinamide Adenine Dinucleotide Phosphate Hydrogen), 5.0 mM G6P (Glucose-6-
Phosphate), 1.7 units/mL G6PDH (Glucose-6-Phosphate Dehydrogenase), 1.0 mM EDTA 
(Ethylenediamine tetraacetic acid) and 3.0 mM magnesium chloride and the reaction was terminated 
at different time intervals. The effect of salicylic acid on CYP2C11 activity is shown in Table 11 and 
Figure 4 and Figure 5. 
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Figure 4. Lineweaver–Burk plot displaying the inhibition of CYP2C11 enzyme on the metabolism of 
testosterone into 16α-hydroxytestosterone using 0-200 µM salicylic acid. Each point represents 
averages of triplicate determinations. 
Table 11. Pharmacokinetic parameters of CYP2C11 inhibition study. Values are expressed as mean ± 
SD (n = 3). Note: p < 0.0001. 
Pharmacokinetic 
Parameters 
No inhibitor 
50 µM Salicylic 
acid 
100 µM Salicylic 
acid 
200 µM Salicylic 
acid 
Km (µM) 
87.5613 ± 
3.0516 
86.5999 ± 3.0855 83.3333 ± 3.2064 80.8335 ± 3.3056 
Vmax 
(µM-1∙min-1) 0.7668 ± 0.1445 0.6581 ± 0.1684 0.5000 ± 0.2216 0.5094 ± 0.2175 
Clint 
(µM−2∙min−1) 0.0087 ± 0.1228 0.0075 ± 0.1425 0.0060 ± 0.1782 0.0063 ± 0.1697 
α' - 1.1651 ± 0.1437 1.5336 ± 0.1092 1.5052 ± 0.1112 
% inhibition - 14.1766 ± 0.6661 34.7967 ± 0.2714 33.5642 ± 0.2814 
 
Figure 5. Inhibition of CYP2C11 isoform by salicylic acid (0–200 µM) in rat liver microsomes. Data 
represent averages of triplicates and are expressed as percentage of remaining control activity. 
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The experimental method for a CYP2C11 assay has been validated in this study for testosterone 
and 16α-hydroxytestosterone. All the analytical parameters (accuracy, precision, % error, % recovery, 
LOD, LOQ, linear regression) were in line with ICH guidelines. 
Our in vitro results demonstrate clearly that salicylic acid, at therapeutically relevant 
concentrations (0–200 µM) [17], acts potently as a reversibly noncompetitive inhibitor, which may 
inhibit cytochrome P450 2C11 enzyme activity, since the calculated Km (substrate concentration at 
which the reaction rate is half of its maximal value) remains unaffected at three salicylic acid 
concentrations (50, 100 and 200 µM). However, the Vmax (maximal rate of the reaction at which enough 
substrate molecules completely fill the enzyme active sites) for the inhibition studies (50, 100 and 200 
µM salicylic acid) decreased compared to the Vmax of the negative control assay, as shown in Table 11 
and in the supplementary data (Table S1, Table S2 and Figure S2). This means that salicylic acid as 
an inhibitor reduces the activity of the CYP2C11 enzyme and is involved in the binding to an allosteric 
site. Thus, salicylic acid weakly inhibits the CYP2C11 enzyme activity with Ki = 84.58 ± 2.67 µM 
(concentration of inhibitor to cause 50% inhibition of original enzyme activity (IC50) = 82.70 ± 2.67 
µM). A higher value of Ki for salicylic acid in rat liver microsomes has a potentially negligible effect 
in causing drug interactions with other co-administrated drugs, which are substrates of the CYP2C11 
enzyme. Outcomes from this in vitro study looking at the inhibitory effect of salicylic acid on 
CYP2C11 enzyme activity will be beneficial for a future in vivo study for healthcare screening for the 
effective use of salicylic acid in clinics and for the safe administration of salicylic acid with other 
drugs. As salicylic acid metabolism is mediated by two CYP450 enzymes (CYP2C11 and CYP2E1) in 
rat liver microsomes, so it will be necessary to evaluate the in vitro and in vivo inhibitory effects of 
salicylic acid on CYP2E1 enzyme activity in humans in order to assess the full effects. 
3. Materials and Methods 
3.1. Materials  
HPLC analytical reagent grade methanol and acetonitrile were purchased from Sigma Aldrich, 
Co. (Old Brickyard, Gillingham, UK). Salicylic acid, potassium phosphate monobasic, potassium 
phosphate dibasic, phenacetin with purity greater than 98%, phosphoric acid (85% w/w), glucose-6-
phosphate (G-6-P), glucose-6-phosphate dehydrogenase (G-6-PDH), EDTA (Ethylenediamine 
tetraacetic acid), NADP+ (Nicotinamide Adenine Dinucleotide Phosphate), magnesium chloride 
(MgCl2), testosterone, microsomes from liver pooled from male rats (Sprague-Dawley) (Gillingham, 
UK) and 16-alfa hydroxytestosterone were purchased from Sigma Aldrich, Co (Old Brickyard, 
Gillingham, UK).  
3.2. Instrument 
A 570 pH Meter purchased from JENWAY Limited (Beacon Road, Stone, Staffordshire, ST15 
0SA, UK) was used. A UV-VIS spectrometry instrument was purchased from VWR International Ltd. 
(Magna Park, Lutterworth, Leicestershire, LE17 4XN, UK) and UV spectra were obtained using a Bio 
100 Cary software from Aglient Technologies LDA (Cheadle Royal Business Park, Stockport, 
Cheshire, SK8 3GR, UK) and 1 cm length of quartz cuvette. A Shimadzu LC-2010A HT Module liquid 
chromatographic system was used (Shimadzu, Tokyo, Japan), combined with a low pressure pump 
quaternary gradient (series 200 LC (Liquid Chromatography) pump), a degasser, a model series 200 
UV-detector, a series 200 Peltier LC column oven for chromatographing the analysed solutions, and 
a series 200 autosampler. A SUPELCO (Fancy Road, Poole, Dorest, BH12 4QH, UK) C18 column (25 
cm × 4.6 mm, 5 µm particle size) was used. The data were processed using Shimadzu HPLC 2 data 
lab solutions software processing system. 
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3.3. CYP450 Assay 
3.3.1. CYP2C11 Substrate and Its Metabolite 
Validation studies were carried out using a LC-2010A HT Module HPLC system (Shimadzu, 
Toyko, Japan). Chromatographic experiments were assessed in a low pressure gradient mode. The 
separation of the four target components (salicylic acid used as a tested inhibitor, phenacetin used as 
an internal standard, testosterone as CYP2C11 substrate and 16α-hydroxytestosterone as CYP2C11 
metabolite) was conducted on a SUPELCO C18 column (25 cm × 4.6 mm, 5 µm particle size). The 
mobile phase for chromatographic separation of the four compounds consisted of 32% of phosphate 
buffer solution (pH = 3.36) and 68% of methanol. The flow rate was set to 0.8 mL/min, and the oven 
temperature was 30 °C. A wavelength detection of 243 nm was used and 10 µL solution volume was 
injected for HPLC analysis. The mobile phase consisted of methanol/phosphate buffer (pH 3.36) 
(68%/32% v/v), which provided good separation and resolution for the investigated compounds. 
3.3.2. Microsomal Incubations and Treatment Protocol 
CYP2C11 activity was determined using testosterone (substrate) via the formation of 16α-
hydroxytestosterone (metabolite for CYP2C11 enzyme). Oxidative metabolism of testosterone was 
measured using a NADPH-regenerating system consisting of: 1.0 mM NADPH (Nicotinamide 
Adenine Dinucleotide Phosphate Hydrogen), 5 mM G6P (Glucose-6-Phosphate), 1.7 units/mL 
G6PDH (Glucose-6-Phospahe Dehydrogenase), 1.0 mM EDTA (Ethylenediamine tetraacetic acid), 
and 3.0 mM magnesium chloride. Mixtures were incubated in a final volume of 500 µL of NADPH-
regenerating system and and a final concentration of 0.067 M potassium phosphate buffer at pH 7.4 
using a serial range of testosterone (25, 50, 100, 150, and 200 µM, dissolved in mobile phase) and a 
serial range of salicylic acid solutions (0, 50, 100 and 200 µM, dissolved in mobile phase), which were 
added to the incubation mixture in triplicate. The reaction was initiated by adding 0.5 mg/mL of 
pooled liver microsomes to each tube. NADP+ (Nicotinamide Adenine Dinucleotide Phosphate) was 
added to the mixture after pre-incubation of all components for 10 min in a water bath at T = 37 °C 
[18]. The final concentration of organic solvent did not exceed the 1% volume. Tubes were incubated 
for 60 min in an Eppendorf thermomixer (Eppendorf UK Limited, Stevenage) at 800 × g (37 oC). The 
reaction was terminated after 65 min by the addition of ice-cold grade acetonitrile containing 50 µM 
of phenacetin (as an internal standard). Tubes were centrifuged in a microcentrifuge (13,000 × g) for 
12 min to precipitate protein. Then, the supernatant was collected and dissolved in a mobile phase 
(30% phosphate buffer at pH 3.36 and 70% methanol) and made up to 1000 µL volume. A volume of 
10 µL of dissolved supernatant was injected into the instrument for HPLC analysis.  
3.4. Selection of Analytical Wavelength 
3.4.1. CYP2C11 Assay 
Phenacetin (50 µM), salicylic acid (100 µM), testosterone (200 µM), and 16α-hydroxytestosterone 
(50 µM) standard solutions were recorded in the UV region of 200–350 nm using methanol as a blank, 
and 243 nm absorption wavelength. 
3.5. Preparation of Mobile Phase 
3.5.1. CYP2C11 Assay 
Different mobile phases for the CYP2C11 assay were used. Thus, the most suitable mobile phase 
was as follows: HPLC grade methanol (low UV cut-off of 205 nm) as mobile phase (A), and phosphate 
buffer at pH = 3.36 as mobile phase (B) (A: 68%, B: 32%).  
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3.6. Preparation of Standard and Sample Solutions 
3.6.1. CYP2C11 Assay 
Analytes Standard Solution Preparation 
Salicylic acid (SA) (1.38 mg) (C = 200 µM) was weighed accurately and dissolved in a 50 mL 
volumetric flask in a mobile phase (70% methanol + 30% phosphate buffer at pH = 3.36). Serial 
dilutions were performed, yielding final concentrations of 150, 100, 75, 50, 25, and 10 µM. 
Testosterone (5.76 mg) (C = 400 µM) was weighed accurately and added to a 50 mL volumetric flask 
before being dissolved in mobile phase. A serial dilution of testosterone stock solution was made, 
yielding final concentrations of 300, 200, 150, 100, 50, and 25 µM. Phenacetin was used as an internal 
standard for the CYP2C11 enzyme assay by dissolving 0.0009 g of the powder in a mobile phase (70% 
methanol + 30% phosphate buffer at pH = 3.36) and a 100 mL volumetric flask. 
Metabolite Standard Solution Preparation 
The metabolite for the CYP2C11 enzyme (16α-hydroxytestosterone) stock solution of 100 µM (in 
a 50 mL volumetric flask) was prepared, followed by serial dilutions to 80, 60, 40, 20 and 10 µM 
respectively. 
3.7. Data Analysis 
The regression equation (standard and calibration curves) consisted of different ranges of 
testosterone and 16α-hydroxytestosterone concentrations using 50 µM of phenacetin as an internal 
standard, which was calculated by a weighted least-squares linear regression analysis of mean peak area 
ratio (peak area of standard/peak area of internal standard) versus standard concentrations. Validation 
parameters were calculated using Microsoft Excel 2010 software (Microsoft Corp. London, UK). 
The CYP inhibition analysis was assessed by measuring the formation of 16α-
hydroxytestosterone metabolite of the tested CYP2C11 substrate (testosterone). The peak area ratios 
of both the metabolite and internal standard were acquired using Microsoft Excel 2010 software. 
Pharmacokinetic parameter (Vm, Km, Clint, α,, Ki) values were obtained from secondary Lineweaver–
Burk and Michaelis–Menten plots. Inhibition data of CYP2C11 assays were assumed as non-
competitive inhibition based on the shape of Lineweaver–Burk plots, and the standard error. AIC 
(Akaike information criterion) and SC (Schwarz criterion) were from obtained nonlinear regression 
analysis. The concentration of inhibitor to cause 50% inhibition of original enzyme activity (IC50) was 
determined by nonlinear regression using Graphpad Prism software (London, UK). The percentage 
inhibition was calculated from Vm values. 
4. Conclusions 
In conclusion, an HPLC method was developed and validated for high throughput screening of 
compounds mediated by the CYP2C11 enzyme using salicylic acid as a tested inhibitor. Optimisation 
for in vitro CYP2C11 enzymatic reaction was achieved with regard to enzyme concentration and 
incubation time of the reaction. The amount of marker metabolite was quantified by a highly accurate 
and sensitive HPLC method. In this study, the in vitro CYP2C11 inhibition assay data demonstrated 
that Salicylic acid acts reversibly as a noncompetitive inhibitor, which may inhibit cytochrome P450 
2C11 enzyme activity. The outcomes obtained provide useful tips for the effective use of salicylic acid 
in clinics. However, further in vitro and in vivo investigational studies are needed to determine the 
effect of salicylic acid administration in humans for full healthcare screening, regarding the safety of 
this drug when administrated concomitantly with regular medicines.  
Supplementary Materials: The following are available online, Figure S1: UV-VIS spectroscopy for Phenacetin 
(internal standard) in the CYP2C11 assay, Table S1: Linear regression, range and limit of detection analysis for 
CYP2C11 assay incubation, Table S2: Outcomes of rat microsomal incubation assays (n=3) of 60 mins incubation 
using different range of Testosterone concentration levels, Figure S2: Bar chart shows the reduction in 
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Testosterone and the formation of 16-alfa hydroxytestosterone after 60 mins of CYP2C11 assay incubation at 
different testosterone concentration levels (25, 50, 100, 150, 200, 300 and 400 µM). 
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